Company’s 36-month beta value is 1.38.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBOT is 23.70M, and currently, short sellers hold a 4.37% ratio of that floaft. The average trading volume of MBOT on January 14, 2025 was 2.17M shares.
MBOT) stock’s latest price update
Microbot Medical Inc (NASDAQ: MBOT)’s stock price has gone decline by -6.74 in comparison to its previous close of 1.78, however, the company has experienced a -41.55% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-01-10 that BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter.
MBOT’s Market Performance
MBOT’s stock has fallen by -41.55% in the past week, with a monthly rise of 62.75% and a quarterly rise of 68.77%. The volatility ratio for the week is 27.80% while the volatility levels for the last 30 days are 15.85% for Microbot Medical Inc The simple moving average for the past 20 days is 16.50% for MBOT’s stock, with a 60.26% simple moving average for the past 200 days.
Analysts’ Opinion of MBOT
Many brokerage firms have already submitted their reports for MBOT stocks, with H.C. Wainwright repeating the rating for MBOT by listing it as a “Buy.” The predicted price for MBOT in the upcoming period, according to H.C. Wainwright is $26 based on the research report published on January 13, 2020 of the previous year 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MBOT reach a price target of $12, previously predicting the price at $10. The rating they have provided for MBOT stocks is “Buy” according to the report published on December 24th, 2019.
Ladenburg Thalmann gave a rating of “Buy” to MBOT, setting the target price at $1.75 in the report published on January 31st of the previous year.
MBOT Trading at 44.08% from the 50-Day Moving Average
After a stumble in the market that brought MBOT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.89% of loss for the given period.
Volatility was left at 15.85%, however, over the last 30 days, the volatility rate increased by 27.80%, as shares surge +73.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +83.25% upper at present.
During the last 5 trading sessions, MBOT fell by -39.09%, which changed the moving average for the period of 200-days by +50.43% in comparison to the 20-day moving average, which settled at $1.4284. In addition, Microbot Medical Inc saw 48.21% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MBOT
Current profitability levels for the company are sitting at:
- -72.27 for the present operating margin
- 0.46 for the gross margin
The net margin for Microbot Medical Inc stands at -78.91. The total capital return value is set at -2.67. Equity return is now at value -200.70, with -158.98 for asset returns.
Currently, EBITDA for the company is -10.63 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 276.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.64.
Conclusion
In a nutshell, Microbot Medical Inc (MBOT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
